Literature DB >> 20046205

Type I interferons: crucial participants in disease amplification in autoimmunity.

John C Hall1, Antony Rosen.   

Abstract

A significant body of data implicates the type I interferon (IFN) pathway in the pathogenesis of autoimmune rheumatic diseases. In these disorders, a self-reinforcing cycle of IFN production can contribute to immunopathology through multiple mechanisms. Type I IFN cytokines are pleiotropic in their effects, mediating antiviral and antitumor activities, and possess numerous immunomodulatory functions for both the innate and adaptive immune responses. A key principle of the type I IFN system is rapid induction and amplification of the signaling pathway, which generates a feed-forward loop of IFN production, ensuring that a vigorous antiviral immune response is mounted. Although such feed-forward pathways are highly adaptive when it comes to rapid and effective virus eradication, this amplification can be maladaptive in immune responses directed against host tissues. Such feed-forward loops, however, create special opportunities for therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20046205      PMCID: PMC3622245          DOI: 10.1038/nrrheum.2009.237

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  120 in total

1.  Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity.

Authors:  Mitsutoshi Yoneyama; Mika Kikuchi; Kanae Matsumoto; Tadaatsu Imaizumi; Makoto Miyagishi; Kazunari Taira; Eileen Foy; Yueh-Ming Loo; Michael Gale; Shizuo Akira; Shin Yonehara; Atsushi Kato; Takashi Fujita
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

2.  Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation.

Authors:  Julie M Curtsinger; Javier O Valenzuela; Pujya Agarwal; Debra Lins; Matthew F Mescher
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

3.  Cell type-specific involvement of RIG-I in antiviral response.

Authors:  Hiroki Kato; Shintaro Sato; Mitsutoshi Yoneyama; Masahiro Yamamoto; Satoshi Uematsu; Kosuke Matsui; Tohru Tsujimura; Kiyoshi Takeda; Takashi Fujita; Osamu Takeuchi; Shizuo Akira
Journal:  Immunity       Date:  2005-07       Impact factor: 31.745

4.  Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus.

Authors:  Snaevar Sigurdsson; Gunnel Nordmark; Harald H H Göring; Katarina Lindroos; Ann-Christin Wiman; Gunnar Sturfelt; Andreas Jönsen; Solbritt Rantapää-Dahlqvist; Bozena Möller; Juha Kere; Sari Koskenmies; Elisabeth Widén; Maija-Leena Eloranta; Heikki Julkunen; Helga Kristjansdottir; Kristjan Steinsson; Gunnar Alm; Lars Rönnblom; Ann-Christine Syvänen
Journal:  Am J Hum Genet       Date:  2005-01-18       Impact factor: 11.025

5.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

6.  IRF-7 is the master regulator of type-I interferon-dependent immune responses.

Authors:  Kenya Honda; Hideyuki Yanai; Hideo Negishi; Masataka Asagiri; Mitsuharu Sato; Tatsuaki Mizutani; Naoya Shimada; Yusuke Ohba; Akinori Takaoka; Nobuaki Yoshida; Tadatsugu Taniguchi
Journal:  Nature       Date:  2005-03-30       Impact factor: 49.962

7.  Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection.

Authors:  Ganesh A Kolumam; Sunil Thomas; Lucas J Thompson; Jonathan Sprent; Kaja Murali-Krishna
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307

8.  Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus.

Authors:  Sean R Christensen; Michael Kashgarian; Lena Alexopoulou; Richard A Flavell; Shizuo Akira; Mark J Shlomchik
Journal:  J Exp Med       Date:  2005-07-18       Impact factor: 14.307

9.  RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement.

Authors:  Christina M Lau; Courtney Broughton; Abigail S Tabor; Shizuo Akira; Richard A Flavell; Mark J Mamula; Sean R Christensen; Mark J Shlomchik; Gregory A Viglianti; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  J Exp Med       Date:  2005-10-31       Impact factor: 14.307

10.  Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy.

Authors:  Livia Casciola-Rosen; Kanneboyina Nagaraju; Paul Plotz; Kondi Wang; Stuart Levine; Edward Gabrielson; Andrea Corse; Antony Rosen
Journal:  J Exp Med       Date:  2005-02-21       Impact factor: 14.307

View more
  111 in total

Review 1.  Interferons in autoimmune and inflammatory diseases: regulation and roles.

Authors:  Divaker Choubey; Kamal D Moudgil
Journal:  J Interferon Cytokine Res       Date:  2011-12       Impact factor: 2.607

Review 2.  Unraveling the genetic component of systemic sclerosis.

Authors:  José Ezequiel Martín; Lara Bossini-Castillo; Javier Martín
Journal:  Hum Genet       Date:  2012-01-05       Impact factor: 4.132

Review 3.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

4.  High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide.

Authors:  Masashi Suzuki; David K Pritchard; Lev Becker; Andrew N Hoofnagle; Natsuko Tanimura; Theo K Bammler; Richard P Beyer; Roger Bumgarner; Tomas Vaisar; Maria C de Beer; Frederick C de Beer; Kensuke Miyake; John F Oram; Jay W Heinecke
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

5.  Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.

Authors:  Barbara Kroczynska; Robert L Rafidi; Beata Majchrzak-Kita; Ewa M Kosciuczuk; Gavin T Blyth; Jacek Jemielity; Zofia Warminska; Diana Saleiro; Swarna Mehrotra; Ahmet Dirim Arslan; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2015-12-08       Impact factor: 5.157

6.  Finding a fairy in the forest: ELF4, a novel and critical element of type I interferon responses.

Authors:  Attila Szabo; Eva Rajnavolgyi
Journal:  Cell Mol Immunol       Date:  2014-03-24       Impact factor: 11.530

Review 7.  Modulation of autoimmune rheumatic diseases by oestrogen and progesterone.

Authors:  Grant C Hughes; Divaker Choubey
Journal:  Nat Rev Rheumatol       Date:  2014-08-26       Impact factor: 20.543

8.  Bisphenol A (BPA) stimulates the interferon signaling and activates the inflammasome activity in myeloid cells.

Authors:  Ravichandran Panchanathan; Hongzhu Liu; Yuet-Kin Leung; Shuk-mei Ho; Divaker Choubey
Journal:  Mol Cell Endocrinol       Date:  2015-08-12       Impact factor: 4.102

9.  Nuclear factor κB subunits RelB and cRel negatively regulate Toll-like receptor 3-mediated β-interferon production via induction of transcriptional repressor protein YY1.

Authors:  Jakub Siednienko; Ashwini Maratha; Shuo Yang; Malgorzata Mitkiewicz; Sinéad M Miggin; Paul N Moynagh
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

10.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.

Authors:  C Andrew Stewart; Hannah Metheny; Noriho Iida; Loretta Smith; Miranda Hanson; Folkert Steinhagen; Robert M Leighty; Axel Roers; Christopher L Karp; Werner Müller; Giorgio Trinchieri
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.